Amedisys Reports Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Piper Jaffray Raises Price Target as Amedisys (AMED) Raises Acquisition Pipeline
November 6, 2015 11:44 AM ESTPiper Jaffray reiterated a Neutral rating on Amedisys (NASDAQ: AMED), and raised the price target to $45.00 (from $42.00), following the company's 3Q report. AMED's acquisition pipeline has increased from 17 potential targets a year ago to over 300. While deal valuations have increased to... More
Amedisys (AMED) Tops Q3 EPS by 1c
November 5, 2015 8:12 AM ESTAmedisys (NASDAQ: AMED) reported Q3 EPS of $0.34, $0.01 better than the analyst estimate of $0.33. Revenue for the quarter came in at $326.44 million versus the consensus estimate of $312.22 million.
Paul B. Kusserow, President and Chief Executive Officer stated, We are encouraged by the companys... More
